This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
SAR441255 improved glycemic control and weight loss compared to dual receptor agonists.
Why it matters
This research highlights a potential new treatment for obesity and diabetes by leveraging multiple hormonal pathways. It may lead to more effective therapies with fewer side effects.
How the study worked
The study involved preclinical testing in rodent models and a mixed-meal tolerance test in healthy human subjects.
What this study cannot tell us
The study primarily involved animal models and a small group of healthy subjects, which may limit the generalizability of the findings.
Read the original research
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.
Cell metabolism, 34(1), 59-74.e10
Citation
Bossart, Martin; Wagner, Michael; Elvert, Ralf; Evers, Andreas; Hübschle, Thomas; Kloeckener, Tim; Lorenz, Katrin; Moessinger, Christine; Eriksson, Olof; Velikyan, Irina; Pierrou, Stefan; Johansson, Lars; Dietert, Gabriele; Dietz-Baum, Yasmin; Kissner, Thomas; Nowotny, Irene; Einig, Christine; Jan, Christelle; Rharbaoui, Faiza; Gassenhuber, Johann; Prochnow, Hans-Peter; Agueusop, Inoncent; Porksen, Niels; Smith, William B; Nitsche, Almut; Konkar, Anish. (2022). Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.. Cell metabolism, 34(1), 59-74.e10. https://doi.org/10.1016/j.cmet.2021.12.005